These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9153956)

  • 1. The role of FasL-induced apoptosis in immune privilege.
    Griffith TS; Ferguson TA
    Immunol Today; 1997 May; 18(5):240-4. PubMed ID: 9153956
    [No Abstract]   [Full Text] [Related]  

  • 2. Cell death and the immune response: a lesson from the privileged.
    Ferguson TA; Griffith TS
    J Clin Immunol; 1997 Jan; 17(1):1-10. PubMed ID: 9049780
    [No Abstract]   [Full Text] [Related]  

  • 3. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A vision of cell death: insights into immune privilege.
    Ferguson TA; Griffith TS
    Immunol Rev; 1997 Apr; 156():167-84. PubMed ID: 9176707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Fas ligand in immune privilege.
    Green DR; Ferguson TA
    Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoregulatory effects of Fas-mediated signalling.
    Lynch DH; Alderson MR; Ramsdell F
    J Cell Biochem; 1996 Jan; 60(1):39-46. PubMed ID: 8825414
    [No Abstract]   [Full Text] [Related]  

  • 7. Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis.
    Eischen CM; Leibson PJ
    Res Immunol; 1997; 148(3):164-9. PubMed ID: 9255868
    [No Abstract]   [Full Text] [Related]  

  • 8. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.
    O'Connell J; Bennett MW; Nally K; Houston A; O'Sullivan GC; Shanahan F
    Ann N Y Acad Sci; 2000 Jun; 910():178-92; discussion 193-5. PubMed ID: 10911913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance.
    Griffith TS; Yu X; Herndon JM; Green DR; Ferguson TA
    Immunity; 1996 Jul; 5(1):7-16. PubMed ID: 8758890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of Fas-Fas ligand interactions in graft rejection.
    Martinez OM; Krams SM
    Int Rev Immunol; 1999; 18(5-6):527-46. PubMed ID: 10672500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to Fas-mediated cell death in BeWo and NJG choriocarcinoma cell lines: implications in immune privilege.
    Rajashekhar G; Loganath A; Roy AC; Mongelli JM
    Gynecol Oncol; 2003 Oct; 91(1):89-100. PubMed ID: 14529667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas-ligand: privilege and peril.
    Green DR; Ware CF
    Proc Natl Acad Sci U S A; 1997 Jun; 94(12):5986-90. PubMed ID: 9177153
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal tubular epithelial cell apoptosis by Fas-FasL-dependent self-injury can augment renal allograft injury.
    Du C; Guan Q; Yin Z; Masterson M; Zhong R; Jevnikar AM
    Transplant Proc; 2003 Nov; 35(7):2481-2. PubMed ID: 14611992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 expression in pig cells suppresses the apoptosis caused by human perforin/granzymes- or FasL/Fas-mediated cytotoxicity.
    Fujiwara I; Nakajima H; Mizuta N; Sakaguchi K; Yoshimura N; Yamagishi H; Oka T
    Transplant Proc; 2000 Aug; 32(5):941-2. PubMed ID: 10936285
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
    O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
    Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of Fas expression in leukemia: questions and controversies.
    Findley HW; Zhou M
    Leukemia; 1999 Feb; 13(2):147-9. PubMed ID: 10025885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis and CD95 ligand in immune privileged sites.
    Bellgrau D; Duke RC
    Int Rev Immunol; 1999; 18(5-6):547-62. PubMed ID: 10672501
    [No Abstract]   [Full Text] [Related]  

  • 18. Apoptosis and autoimmune thyroid disease: following a TRAIL to thyroid destruction?
    Bretz JD; Baker JR
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):1-11. PubMed ID: 11453945
    [No Abstract]   [Full Text] [Related]  

  • 19. THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells.
    Bremner TA; Chatterjee D; Han Z; Tsan MF; Wyche JH
    Leuk Res; 1999 Oct; 23(10):865-70. PubMed ID: 10573130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology.
    Webb SD; Sherratt JA; Fish RG
    Math Biosci; 2002; 179(2):113-29. PubMed ID: 12208611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.